Global Monitoring Plan

Researchers to Return to the Site of NORI’s Nodule Collection System Test to Assess Seafloor Ecosystem Function A Year After the Test

Retrieved on: 
Wednesday, November 8, 2023
Science, Social impact assessment, ISA, Clipperton Fracture Zone, Environmental resource management, Biota, International Seabed Authority, Research, Engineering, ESIA, Allseas, TMC, The Metals Company, Global Monitoring Plan, Specialization, Dredging, Rare-earth element

The upcoming offshore campaign is the latest in The Metals Company subsidiary NORI’s Environmental and Social Impact Assessment (ESIA) to characterise the potential impacts of proposed polymetallic nodule collection operations.

Key Points: 
  • The upcoming offshore campaign is the latest in The Metals Company subsidiary NORI’s Environmental and Social Impact Assessment (ESIA) to characterise the potential impacts of proposed polymetallic nodule collection operations.
  • Scientists from several leading marine research institutions will undertake an array of studies on the site of last year’s nodule collection system test to gather further environmental data on ecosystem recovery and functioning.
  • The Company expects to commence the campaign in Q4 2023.
  • Specialized research teams will use an array of boxcore and multi-core samplers as well as various benthic lander systems to assess impacts to biota and ecosystem function on the seafloor in NORI-D.

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma

Retrieved on: 
Monday, July 24, 2023
DNA, University, Global Monitoring Plan, Multiple myeloma, Writing, Monroe Dunaway Anderson, Haematopoietic system, Trial of the century, MD Anderson Cancer Center, Sarcoma, Investigational New Drug, Patient, MD, NY-ESO-1, Biology, Entrepreneurship, FDA, IND, Genome, Bone marrow, Pharmaceutical industry, Replay

MD Anderson is the IND sponsor.

Key Points: 
  • MD Anderson is the IND sponsor.
  • NY-ESO-1 TCR/IL-15 NK is being developed by Syena, an oncology-focused product company launched by Replay and MD Anderson based upon the scientific discoveries of Katy Rezvani , M.D., Ph.D. , professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson.
  • Syena has an exclusive licensing agreement for MD Anderson’s TCR-NK platform.
  • “I look forward to the study beginning later this year.”
    MD Anderson has an institutional conflict of interest with Replay and Syena, and MD Anderson will implement an Institutional Conflict of Interest Management and Monitoring Plan to manage these relationships.

Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma

Retrieved on: 
Tuesday, June 20, 2023
Synovial sarcoma, DNA, University, Global Monitoring Plan, Writing, Monroe Dunaway Anderson, Cell, Haematopoietic system, TCR, Science, MD Anderson Cancer Center, Investigational New Drug, Patient, MD, NY-ESO-1, Biology, Entrepreneurship, FDA, Safety, IND, Genome, Pharmaceutical industry, Replay

NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, Replay and MD Anderson’s first-in-class engineered TCR-NK cell therapy company.

Key Points: 
  • NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, Replay and MD Anderson’s first-in-class engineered TCR-NK cell therapy company.
  • NY-ESO-1 TCR/IL-15 NK is being developed by Syena, an oncology-focused product company launched by Replay and MD Anderson based upon the scientific discoveries of Katy Rezvani, M.D., Ph.D. , professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson.
  • "Syena is leveraging the scalability and allogeneic nature of engineered cord blood-derived NK cells to democratize cell therapy for cancer treatment.
  • The recent FDA IND clearance of the first-in-human TCR-NK protocol is a significant milestone for Syena," said Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay.

KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy

Retrieved on: 
Tuesday, February 14, 2023
TCR, DNA, Science, Monroe Dunaway Anderson, Bone marrow, MD Anderson Cancer Center, Anderson, Global Monitoring Plan, CAR, Protein, NEJM, Biology, Medicine, Intellectual property, Safety, Liu, NK, Patient, Entrepreneurship, Clinical trial, Cell, University, Writing, Research, KKR, Haematopoietic system, MD, NY-ESO-1, Genome, Pharmaceutical industry, Vaccine, Replay

The new company’s TCR-NK cell platform is based upon the scientific discoveries of Katy Rezvani, M.D., Ph.D. , professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson.

Key Points: 
  • The new company’s TCR-NK cell platform is based upon the scientific discoveries of Katy Rezvani, M.D., Ph.D. , professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson.
  • “This first-in-class TCR-NK technology provides an opportunity for Replay to disrupt the existing cell therapy paradigm and positions Syena to become a leader in this space,” said Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay.
  • “While clinical successes in hematological malignancies have demonstrated the transformative potential of engineered cell therapies, these successes have not yet been realized in solid tumors.
  • “We are delighted to have Dr. Rezvani, a world-leading expert in NK-based cell therapy and pioneer of CAR-NK cell therapy, as the scientific founder of Syena,” said Lachlan MacKinnon, CEO and Co-Founder of Replay.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Peripheral T-cell lymphoma, Investigational New Drug, Global Monitoring Plan, Cell, University, FDG-PET, NK, Patient, Anderson, Clinical trial, CST, Haematopoietic system, Aplastic anemia, Terrorism, Cytokine release syndrome, Hodgkin lymphoma, Macrophage, Lymphoma, Cancer, DOR, Biotechnology, Toxic epidermal necrolysis, ASH, CD30, Affimer, REDIRECT, CR, CFGB-FM, ORR, EST, Growth, Research, ID, NHL, MD Anderson Cancer Center, Cyclophosphamide, Society, COVID-19, Lead, Pharmaceutical industry, Vaccine, Hospital

Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile.

Key Points: 
  • Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile.
  • Across all 35 patients treated at the RP2D, a 94% ORR and a CR rate of 71% were observed.
  • “It’s impressive that we continue to see these response rates in a patient population that has exhausted all other treatment options.
  • Session: Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma
    Affimed will host an investor event to review AFM13 clinical data and development plans in CD30-expressing malignancies.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Retrieved on: 
Monday, November 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, U.S. News & World Report, Hospital, NCI, MD Anderson Cancer Center, Anderson, SEC filing, IACS, Drug development, Therapy, Patient, P30, Science, News, Precision medicine, Medicine, Cancer, Deep learning, Research, Security (finance), Physician, Risk, Annual report, Monroe Dunaway Anderson, Education, University, COVID-19, Drug discovery, Judgement, Therapeutic discovery project, Artificial intelligence, Global Monitoring Plan, National Cancer Institute, MD, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
  • Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics.
  • We are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments.
  • Under the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.

Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Haematopoietic system, Society, University, LSC, ADCC, Clinical trial, Macrophage, LSCS, SEC, Terrorism, Department, Program, Growth, 2021 Essex County Council election, CST, GLOBE, NK, ASH, CR, Affimer, Forward-looking statement, GVHD, Patient, CFGB-FM, Cancer, ORR, MDS, Research, Drug resistance, Biotechnology, Global Monitoring Plan, COVID-19, Heidelberg University, CD123, REDIRECT, Pharmacology, Exposition, DL2, Serum, Lead, Industry, Cell, Cytokine release syndrome, Poster, CRS, Acute myeloid leukemia, Myelodysplastic syndrome, MD Anderson Cancer Center, Investigator's brochure, Lymphoma, CD30, IRR, EFS, AML, Pharmaceutical industry, Vaccine, Hematology

Each cycle of treatment consists of a lymphodepletion, followed by single dose of AFM13 precomplexed with cbNK cells and three subsequent infusions of AFM13 monotherapy.

Key Points: 
  • Each cycle of treatment consists of a lymphodepletion, followed by single dose of AFM13 precomplexed with cbNK cells and three subsequent infusions of AFM13 monotherapy.
  • In a panel of AML cell lines, AFM28 successfully engaged allogeneic NK cells to destroy CD123-positive tumor cells through antibody-dependent cytotoxicity (ADCC).
  • AFM28 is currently being prepared for a first-in-human clinical investigation as monotherapy and in combination with allogeneic NK cells.
  • Clinical development is planned as both monotherapy and in combination with allogeneic NK cells in patients with relapsed/refractory CD123-positive leukemias.

SodaStream, The World's Leading Sparkling Water Brand, Unveils a 360° Repositioning

Retrieved on: 
Tuesday, September 13, 2022
YouTube, Human voice, Digital, PepsiCo, SodaStream, Duo, Global Monitoring Plan, Collection, Kantar, Nature, Partnership, Visual language, CEO, Instagram, Art, Food, Heart, S, Water, Attitude, Bottled water, Sand, Facebook

Comprehensive Rebranding Including New Visual Design, Packaging, Digital, and Tone of Voice

Key Points: 
  • Comprehensive Rebranding Including New Visual Design, Packaging, Digital, and Tone of Voice
    TORONTO, Sept. 13, 2022 /CNW/ - SodaStream, the world's leading sparkling water brand announces a full 360 brand-repositioning going live today.
  • At the heart of the new positioning is the brand's call to Push for Better, inspired by the action one takes when pushing the SodaStream sparkling water maker button.
  • "As the experts of sparkling beverages creation, we are excited to provide our consumers with the perfect sparkling water experiences, with an upgraded lifestyle.
  • SodaStream, a PepsiCo subsidiary, is the world's leading sparkling water brand.